Gastrin I (human): Advanced Applications in CCK2 Receptor Signaling and Intestinal Organoid Models

Introduction

Gastrin I (human) is a pivotal endogenous regulatory peptide that has long served as a critical tool in gastrointestinal research, particularly for elucidating the mechanisms underlying gastric acid secretion and CCK2 receptor signaling. With a molecular weight of 2098.22 Da and a well-characterized receptor-mediated mode of action, Gastrin I (human) enables precise in vitro interrogation of gastric acid secretion pathways, proton pump activation, and gastrointestinal physiology. Recent advances in stem cell-derived organoid technologies have further expanded the utility of this peptide, offering new opportunities to model human intestinal biology, investigate disease mechanisms, and examine pharmacokinetic processes in a controlled, human-relevant setting. This article provides a comprehensive overview of the scientific applications of human Gastrin I peptide, emphasizing its integration with next-generation intestinal organoid systems and its value in gastrointestinal disorder research.

Molecular and Functional Profile of Gastrin I (human)

Gastrin I (human), CAS number 10047-33-3, is an amidated peptide hormone secreted primarily by G cells of the gastric antrum. Its major biological function is to stimulate gastric acid secretion by binding to the cholecystokinin B/gastrin receptor (CCK2 receptor) on gastric parietal cells. This binding triggers a cascade of intracellular events, notably the activation of phospholipase C, elevation of intracellular calcium, and subsequent activation of the H⁺/K⁺-ATPase (proton pump), thereby increasing acid output. Due to its high purity (≥98% by HPLC and mass spectrometry) and solubility profile—insoluble in water and ethanol but readily soluble in DMSO—Gastrin I (human) is well-suited for in vitro studies that require reproducibility and specificity.

CCK2 Receptor Agonism and Receptor-Mediated Signal Transduction

The interaction between Gastrin I and the CCK2 receptor is central to its role as a gastric acid secretion regulator and as a model ligand for investigating receptor-mediated signal transduction. Upon agonist binding, the CCK2 receptor, a G protein-coupled receptor (GPCR), initiates downstream signaling that not only activates the gastric proton pump but also modulates gene expression profiles pertinent to cell proliferation and differentiation within the gastric mucosa. Detailed analysis of CCK2 receptor signaling has broad relevance, extending from basic gastrointestinal physiology studies to the mechanistic exploration of hypergastrinemic states in pathologies such as Zollinger-Ellison syndrome and gastric neoplasia.

Integration of Gastrin I (human) in Intestinal Organoid-Based Research

Recent technological advances in human pluripotent stem cell (PSC)-derived organoid systems have created new frontiers for in vitro gastrointestinal research. As described by Saito et al. (European Journal of Cell Biology, 2025), human induced pluripotent stem cell (hiPSC)-derived intestinal organoids (IOs) now enable the faithful recapitulation of mature intestinal epithelial cell types, including enterocytes, goblet cells, and enteroendocrine cells, which are critical for absorption, metabolism, and barrier functions. These organoids display functional cytochrome P450 enzyme activity and transporter profiles relevant for pharmacokinetic assessment.

Within this context, the use of Gastrin I (human) facilitates the study of CCK2 receptor signaling pathways in a physiologically relevant, human-derived system. Employing this peptide in organoid cultures allows for the dissection of paracrine and autocrine signaling mechanisms, including the regulation of stem cell niche maintenance, epithelial proliferation, and the differentiation of enteroendocrine cell populations. Moreover, the peptide’s role as a model agonist is instrumental in evaluating the pharmacological response to CCK2 receptor modulation, which is particularly valuable for translational studies targeting gastrointestinal disorders.

Proton Pump Activation and Gastric Acid Secretion Pathway Research

One of the canonical applications of Gastrin I (human) is in the study of proton pump activation within gastric parietal cells. The peptide’s ability to reproducibly activate H⁺/K⁺-ATPase, the primary effector of gastric acid secretion, renders it indispensable for dissecting the molecular events governing acid production. In vitro models employing human Gastrin I peptide permit controlled investigation of the upstream and downstream effectors in the gastric acid secretion pathway, including the roles of histamine, acetylcholine, and somatostatin in modulating acid output.

Importantly, these models support the assessment of proton pump inhibitors and other therapeutic agents under conditions that closely mimic physiological and pathological acid secretion dynamics. By integrating Gastrin I (human) stimulation with genetically engineered cell lines or organoid systems, researchers can explore both acute and chronic responses to receptor activation, enabling high-resolution mapping of signal transduction networks.

Gastrointestinal Disorder Research: Mechanistic Insights and Drug Discovery

The application of Gastrin I (human) extends beyond basic physiology to encompass gastrointestinal disorder research. Hypergastrinemia and aberrant CCK2 receptor signaling are implicated in disorders such as gastric ulcers, gastrinomas, and certain subtypes of gastric cancer. Experimental models utilizing Gastrin I (human) allow for the study of dysregulated acid secretion and the downstream effects on epithelial integrity, inflammation, and neoplastic transformation.

Furthermore, the integration of this peptide into organoid-based disease models provides an advanced platform for preclinical drug screening, enabling the evaluation of candidate compounds targeting the CCK2 receptor pathway. This is particularly pertinent in the context of stem cell-derived IOs, which, as shown by Saito et al. (2025), exhibit human-specific pharmacokinetic features that are often absent in traditional animal models or immortalized cell lines. As such, Gastrin I (human) serves as a benchmark agonist in testing the efficacy and specificity of novel therapeutics aimed at modulating gastric acid secretion and mitigating disease progression.

Technical Considerations for In Vitro Applications

For reliable experimental outcomes, the physicochemical and storage properties of Gastrin I (human) must be considered. The peptide is supplied as a white lyophilized solid, stable when stored desiccated at -20°C, and should be dissolved in DMSO at concentrations ≥21 mg/mL immediately prior to use. Long-term storage of peptide solutions is not recommended due to potential degradation; thus, freshly prepared aliquots are advised for each experiment. The high purity of the product, as verified by HPLC and mass spectrometry, ensures minimal batch-to-batch variability, supporting reproducible results in both traditional cell culture and advanced 3D organoid systems.

Practical Guidance: Optimizing Experimental Design with Gastrin I (human)

When incorporating Gastrin I (human) in gastrointestinal physiology studies or pharmacokinetic assays, careful titration of peptide concentration and exposure duration is essential to capture both acute and sustained signaling events. Researchers should consider the expression profile of CCK2 receptors in their chosen model system—whether parietal cell-enriched cultures, stem cell-derived organoids, or engineered epithelial monolayers—to optimize responsiveness and data interpretation. The use of pathway-specific inhibitors or receptor antagonists can further delineate the specificity of observed effects, providing mechanistic clarity for both basic and translational research objectives.

Future Directions: Expanding the Utility of Gastrin I (human) in Organoid Technologies

The convergence of high-purity peptide reagents like Gastrin I (human) with scalable, genetically tractable organoid models heralds a new era in gastrointestinal research. As protocols for the differentiation and long-term maintenance of hiPSC-derived IOs continue to evolve, there is growing potential to model patient-specific disease states, interrogate genotype-phenotype relationships, and perform high-throughput drug screening in a human-relevant context. The peptide’s robust ability to activate CCK2 receptor signaling within these systems provides a foundation for exploring inter-individual variability in drug response and for uncovering novel therapeutic targets in complex gastrointestinal disorders.

Conclusion

Gastrin I (human) stands at the intersection of classical pharmacology and modern organoid-based research, offering a versatile platform for investigating gastric acid secretion regulation, CCK2 receptor signaling, and the pathophysiology of gastrointestinal disorders. Its application in hiPSC-derived intestinal organoids, as detailed by Saito et al. (2025), represents a significant advancement over traditional models, enabling more accurate and translationally relevant insights into human gastrointestinal biology and disease. For researchers seeking to dissect the nuances of receptor-mediated signal transduction or to evaluate novel therapeutics in a humanized system, Gastrin I (human) remains an indispensable experimental tool.

Contrast with Existing Literature: Unlike prior articles such as "Gastrin I (human) in Intestinal Organoid Research: Advances and Perspectives", which primarily focus on the general adoption of Gastrin I in organoid culture and GI physiology, this article delivers a deeper mechanistic exploration of CCK2 receptor signaling and integrates recent advances in hiPSC-derived organoid pharmacokinetic modeling. By explicitly tying peptide-mediated receptor activation to translational drug discovery and providing detailed guidance for experimental design, this piece addresses both technical and conceptual gaps left by previous reviews, offering a uniquely comprehensive resource for the scientific community.